"We will continue to monitor the success of ramdevpir in clinical trials across the country to provide the best results for British patients".
June Raine, chief executive of the MHRA, said that the organisation was "committed" to ensuring that patients had fast access to promising new treatments for COVID-19.
Thanks to the joined-up efforts of the United Kingdom government, the devolved administrations, pharmaceutical company Gilead Sciences, the NHS, and the Medicines and Healthcare products Regulatory Agency (MHRA), the anti-viral drug remdesivir will be made available to patients meeting certain clinical criteria to support their recovery in hospital. The Kaplan-Meier estimates of mortality by 14 days were 7.1 and 11.9 percent with remdesivir and placebo, respectively (hazard ratio for death, 0.70; 95 percent confidence interval, 0.47 to 1.04).
The researchers, including those from the New York University in the USA, found that remdesivir was most beneficial for hospitalised patients with severe disease requiring supplemental oxygen. Investigators found that remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen.
The government today (May 26) announced that selected patients with severe Covid-19 will be allowed to be treated with remdesivir. The findings are statistically significant and are based on an analysis of 1059 participants (538 who received remdesivir and 521 who received placebo).
The scientific opinion describes the risks and benefits of the medicine based on data gathered from the patients who will benefit from the medicine.
"We are awaiting final visits, data entry, monitoring, and data lock for the last of the 1063 patients enrolled, after which an update of the results will be provided", the researchers noted in the study.
From this week, some patients will be given remdesivir to help speed up their recovery.
Research being carried out on remdesivir in Germany.
"There was not sufficient detail in the paper to check whether they adequately adjusted for potential confounders - the authors themselves said you cannot judge a drug's safety on the data that they were using, which you can't - you need randomised control trials, which is why trials like PRINCIPLE exist", he explained.
Get all the latest news on coronavirus and more delivered daily to your inbox.
A drug treatment called remdesivir that appears to shorten recovery time for people with coronavirus is being made available on the NHS.
The WHO has launched a review of the data it has in hand from the chloroquine and hydroxychloroquine arms in SOLIDARITY, but will continue dosing patients in the other arms that are testing remdesivir, AbbVie's HIV drug Kaletra (lopinavir/ritonavir) and interferon beta-1a.